Abstract:Background Antitumor immunity is highly heterogeneous between individuals; however, underlying mechanisms remain elusive, despite their potential to improve personalized cancer immunotherapy. Head and neck squamous cell carcinomas (HNSCCs) vary significantly in immune infiltration and therapeutic responses between patients, demanding a mouse model with appropriate heterogeneity to investigate mechanistic differences. Methods We developed a unique HNSCC mouse model to investigate underlying mechanisms of heterogeneous antitumor immunity. This model system may provide a better control for tumor-intrinsic and host-genetic variables, thereby uncovering the contribution of the adaptive immunity to tumor eradication. We employed single-cell T-cell receptor (TCR) sequencing coupled with single-cell RNA sequencing to identify the difference in TCR repertoire of CD8 tumor-infiltrating lymphocytes (TILs) and the unique activation states linked with different TCR clonotypes. Results We discovered that genetically identical wild-type recipient mice responded heterogeneously to the same squamous cell carcinoma tumors orthotopically transplanted into the buccal mucosa. While tumors initially grew in 100% of recipients and most developed aggressive tumors, ~25% of recipients reproducibly eradicated tumors without intervention. Heterogeneous antitumor responses were dependent on CD8 T cells. Consistently, CD8 TILs in regressing tumors were significantly increased and more activated. Single-cell TCR-sequencing revealed that CD8 TILs from both growing and regressing tumors displayed evidence of clonal expansion compared with splenic controls. However, top TCR clonotypes and TCR specificity groups appear to be mutually exclusive between regressing and growing TILs. Furthermore, many TCRα/TCRβ sequences only occur in one recipient. By coupling single-cell transcriptomic analysis with unique TCR clonotypes, we found that top TCR clonotypes clustered in distinct activation states in regressing versus growing TILs. Intriguingly, the few TCR clonotypes shared between regressors and progressors differed greatly in their activation states, suggesting a more dominant influence from tumor microenvironment than TCR itself on T cell activation status. Conclusions We reveal that intrinsic differences in the TCR repertoire of TILs and their different transcriptional trajectories may underlie the heterogeneous antitumor immune responses in different hosts. We suggest that antitumor immune responses are highly individualized and different hosts employ different TCR specificities against the same tumors, which may have important implications for developing personalized cancer immunotherapy.

Heterogeneity and subtypes of CD4+ regulatory T cells: implications for tumor therapy

CTLs heterogeneity and plasticity: implications for cancer immunotherapy

Phenotypic and spatial heterogeneity of CD8+ tumour infiltrating lymphocytes

Generation and Regulation of CD8(+) Regulatory T Cells.

T helper 17 cells and tumor immunity

Roles of CD4+CD25(high) FOXP3+ Tregs in lymphomas and tumors are complex.

Regulatory T cells in tumor immunity

Advance in the Study of CD4~+CD25~+FOXP3~+ Regulatory T Cell in Tumor Immune Evasion

CD8+ T cell states in human cancer: insights from single-cell analysis

Tumor-infiltrating T lymphocytes: friends or foes?

Regulatory T‐cell development in the tumor microenvironment

Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects

The Four Types of Tregs in Malignant Lymphomas

Single-cell RNA-sequencing analyses identify heterogeneity of CD8+ T cell subpopulations and novel therapy targets in melanoma

Differentiation fate of a stem-like CD4 T cell controls immunity to cancer

Treg plasticity and human diseases

Tumor-infiltrating Regulatory T Cells: Origins and Features

Transcriptional heterogeneity in cancer-associated regulatory T cells is predictive of survival.

Human Gamma Delta T-Cell Subsets And Their Involvement In Tumor Immunity

CD8 T-cell subsets: heterogeneity, functions, and therapeutic potential

Differences in TCR repertoire and T cell activation underlie the divergent outcomes of antitumor immune responses in tumor-eradicating versus tumor-progressing hosts